KR20200123184A - 증식이상 장애를 치료하기 위한 물질 및 방법 - Google Patents

증식이상 장애를 치료하기 위한 물질 및 방법 Download PDF

Info

Publication number
KR20200123184A
KR20200123184A KR1020207026863A KR20207026863A KR20200123184A KR 20200123184 A KR20200123184 A KR 20200123184A KR 1020207026863 A KR1020207026863 A KR 1020207026863A KR 20207026863 A KR20207026863 A KR 20207026863A KR 20200123184 A KR20200123184 A KR 20200123184A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
cancer
haloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207026863A
Other languages
English (en)
Korean (ko)
Inventor
요시유키 푸카세
마크 듀건
한스-귀도 웬델
카미니 싱
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20200123184A publication Critical patent/KR20200123184A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
KR1020207026863A 2018-02-19 2019-02-18 증식이상 장애를 치료하기 위한 물질 및 방법 Ceased KR20200123184A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632372P 2018-02-19 2018-02-19
US62/632,372 2018-02-19
PCT/US2019/018441 WO2019161345A1 (en) 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases

Publications (1)

Publication Number Publication Date
KR20200123184A true KR20200123184A (ko) 2020-10-28

Family

ID=67619605

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026863A Ceased KR20200123184A (ko) 2018-02-19 2019-02-18 증식이상 장애를 치료하기 위한 물질 및 방법

Country Status (9)

Country Link
US (2) US12215090B2 (https=)
EP (1) EP3755693B1 (https=)
JP (1) JP2021513963A (https=)
KR (1) KR20200123184A (https=)
CN (1) CN112351977A (https=)
AU (1) AU2019221837B2 (https=)
CA (1) CA3091642A1 (https=)
IL (1) IL276639A (https=)
WO (1) WO2019161345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149942B (zh) * 2021-02-10 2023-06-02 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种洛克米兰醇酚羟基衍生物、其制备方法和应用
WO2022221519A1 (en) * 2021-04-14 2022-10-20 Memorial Sloan-Kettering Cancer Center Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof
CN121712777A (zh) * 2023-08-18 2026-03-20 皇家学术促进机构麦吉尔大学 Rna解旋酶抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
AUPQ866500A0 (en) 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
US7816544B2 (en) 2004-03-23 2010-10-19 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
CA2652873A1 (en) 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
EP2189158A1 (en) 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
WO2015085221A2 (en) 2013-12-05 2015-06-11 Memorial Sloan Kettering Cancer Center Methods for identifying anti-cancer compounds
JP6306481B2 (ja) 2014-03-17 2018-04-04 株式会社神戸製鋼所 延性及び曲げ性に優れた高強度冷延鋼板および高強度溶融亜鉛めっき鋼板、並びにそれらの製造方法
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) * 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
US10639378B2 (en) * 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
US20200392099A1 (en) 2020-12-17
US12215090B2 (en) 2025-02-04
EP3755693A4 (en) 2021-08-04
AU2019221837B2 (en) 2024-08-01
IL276639A (en) 2020-09-30
WO2019161345A1 (en) 2019-08-22
AU2019221837A1 (en) 2020-09-03
CN112351977A (zh) 2021-02-09
CA3091642A1 (en) 2019-08-22
EP3755693A1 (en) 2020-12-30
JP2021513963A (ja) 2021-06-03
EP3755693B1 (en) 2024-06-12
US20250361218A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
CN105646389B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
RU2733750C2 (ru) Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
CN110256421A (zh) Kras-g12c抑制剂
WO2016041489A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
WO2003074525A1 (fr) Compose heterocyclique azote
WO2023138541A1 (zh) 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
WO2003103654A1 (ja) ＮＦ−κＢ活性化阻害剤
JP2001504109A (ja) ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途
WO2022105852A1 (zh) 三嗪二酮类衍生物、其制备方法及其在医药上的应用
WO2023061406A1 (zh) 含三并环结构的parp抑制剂、及其制备方法和医药用途
CN114008028A (zh) 抑制癌细胞生长的嘧啶衍生物及其医药用途
JP2017533237A (ja) 強力なγ−セクレターゼモジュレータ
KR101710740B1 (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
JP7531506B2 (ja) アクリル含有核輸送モジュレーターおよびその使用
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
KR20250009417A (ko) 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도
CN119110795A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
RU1777601C (ru) Способ получени производных тиоурацила или их фармацевтически приемлемых кислотно-аддитивных солей
TWI847445B (zh) 一種噠嗪類化合物、其藥物組合物及應用
JPH11209284A (ja) 骨形成促進剤
JP7025542B2 (ja) Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール
WO1999002527A1 (fr) Derives de naphthyridine
AU2006227101A1 (en) Methods for treating or preventing acute myelogenous leukemia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220217

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240614

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240822

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D